Michal Galek-Aldridge | Health Sciences | Best Scholar Award

Mr. Michal Galek-Aldridge | Health Sciences | Best Scholar Award

University Medical Center Utrecht | Netherland

Michał Gałek-Aldridge is a multilingual medical researcher and physician with a strong interdisciplinary background bridging molecular science, engineering, and regenerative medicine. Born on September 18, 1993, in Tucson, Arizona, he holds Polish nationality and is fluent in English, Dutch, Polish, and Russian, with advanced proficiency in French and beginner-level Portuguese. Michał’s academic journey spans multiple international institutions, including The British School of Warsaw, the Anglo-American School in Moscow, and the International School of Amsterdam, culminating in an International Baccalaureate (IB) bilingual diploma in 2011. He pursued a Bachelor of Science in Molecular Science and Technology at Delft University of Technology and Leiden University, completing his thesis on “The loading of chemotherapeutics in polymersome carriers” at the Reactor Institute Delft. During this period, Michał received an Erasmus Mundus scholarship to study at Chalmers University in Sweden, where he expanded his expertise in nuclear chemistry, project management, waste management, and ecology. Driven by a passion for medicine, he subsequently earned both a Bachelor and Master of Science in Medicine at the University of Amsterdam, with clinical experience in orthopedic surgery at the UMC Amsterdam. Since 2021, Michał has been a PhD candidate at the University Medical Center Utrecht, focusing on the translation of regenerative surgical shoulder implants into clinical practice. His research integrates advanced therapies, 3D-printed medical devices, and regenerative medicine, while also addressing regulatory compliance, intellectual property assessment, and GMP evaluation for ATMP production. He actively supervises students at the 3D Lab, contributing to both academic and translational research. His work is supported by prominent supervisors including Prof. Michel van den Bekerom, Dr. Arthur van Noort, Dr. Bart van der Wal, and Prof. Jos Malda. Michał has contributed extensively to the scientific literature, publishing as first author on innovative orthopedic treatments and as co-author in high-impact journals, including The Lancet Respiratory Medicine, Journal of Shoulder and Elbow Surgery, and JSES Reviews, Reports & Techniques. His research has spanned topics from patient-specific bone regenerative implants and congenital hip dislocation management to COVID-19 respiratory subphenotypes and ventilation strategies. Michał’s professional development is complemented by diverse certifications and conferences, including Medical Device Regulation (EU MDR 2018), ISO 13485, 3D printing in hospitals, and arthroscopy and arthroplasty courses. Outside of his professional endeavors, he maintains an active lifestyle through kickboxing, Muay Thai, skiing, kite surfing, and cooking. His combination of scientific rigor, clinical expertise, and entrepreneurial initiative positions him as a rising leader in regenerative medicine and medical innovation.

Profile: Scopus

Featured Publications

van Spanning, S. H., van Iersel, T. P., Verweij, L. P. E., van Noort, A., Floor, S., Galek-Aldridge, M., van den Borne, M. P. J., Kleinlugtenbelt, Y. V., van den Bekerom, M. P. J., & van Deurzen, D. F. P. (2025). Lower education level is associated with failure to return to sport whereas bony Bankart lesions predict successful return to preinjury sport level after open Latarjet procedure. Arthroscopy: The Journal of Arthroscopic & Related Surgery. Advance online publication.

 

Jitendra Patil | Health Sciences | Best Researcher Award

Mr. Jitendra Patil | Health Sciences | Best Researcher Award

Mr. Jitendra Patil | Sankalchand Patel University Visnagar,Badoda | India

Mr. Jitendra Hilal Patil, Lecturer at H.R. Patel Institute of Pharmaceutical Education and Research, Shirpur, is a PCI-registered academic with a strong background in pharmaceutical sciences and nanotechnology. He holds an M.Pharm in Quality Assurance and is pursuing his Ph.D. at Sankalchand Patel University, Visnagar. His research focuses on developing pH-responsive nanocarrier drug delivery systems for targeted cancer therapy, with publications in Scopus-indexed journals and one patent under process. With a citation index of 29, his innovative work contributes significantly to advancing precision medicine while minimizing systemic toxicity in anticancer treatments.

Author Profile 

Scopus

Education

From the very beginning of his educational journey, Mr. Jitendra Hilal Patil demonstrated a keen interest in pharmaceutical sciences and biomedical research. His strong academic foundation was built through consistent excellence across secondary and higher secondary education, which he pursued with dedication and discipline. His pursuit of a Bachelor’s and Master’s degree in Pharmacy further sharpened his knowledge in drug formulation, quality assurance, and advanced pharmaceutical principles. These formative academic years not only shaped his scientific mindset but also ignited his passion for research in nanotechnology and innovative drug delivery systems. His pursuit of a Ph.D. reflects his commitment to expanding the boundaries of knowledge and contributing to global healthcare challenges.

Experience

Mr. Patil serves as a Lecturer at H.R. Patel Institute of Pharmaceutical Education and Research, Shirpur, where he plays a pivotal role in nurturing future pharmacists and researchers. His teaching approach integrates theory with practical insights, encouraging students to think critically about real-world healthcare challenges. Alongside his teaching responsibilities, he actively engages in research, ensuring his academic contributions are aligned with the latest developments in pharmaceutical innovation. His ability to balance teaching, research, and mentoring highlights his versatility as both an educator and a researcher. He also ensures his students are exposed to cutting-edge topics such as nanotechnology, targeted therapies, and drug delivery systems, preparing them to excel in the evolving landscape of pharmaceutical sciences.

Research Focus

The hallmark of Mr. Patil’s academic journey lies in his research on pH-responsive nanocarrier drug delivery systems designed for targeted cancer treatment. Recognizing the limitations of conventional chemotherapy—such as poor survival rates, systemic toxicity, and severe side effects—he focused on developing titanium-based metal-organic frameworks (Ti-MOFs) as nanocarriers for the anticancer drug axitinib (AXT).

Through advanced hydrothermal synthesis and characterization techniques, he successfully developed stable, porous nanostructures that exhibit excellent pH-responsive behavior. His in vitro studies revealed that these carriers released minimal drug amounts in neutral pH, simulating healthy tissues, but significantly increased release in acidic environments mimicking cancer cells. This innovation represents a major step toward precision medicine, offering the potential to reduce toxicity and enhance therapeutic efficacy. His work exemplifies how nanotechnology can transform oncology treatments, opening doors to more effective and patient-friendly therapies.

Awards and Recognition

Mr. Patil’s research has garnered recognition through Scopus-indexed publications, citations, and a patent under process, highlighting the originality and applicability of his work. With a citation index of 29, his publications demonstrate a meaningful academic impact and a growing influence in the pharmaceutical research community. He is also a registered member of the Pharmacy Council of India (PCI), further strengthening his professional credibility. While he has not yet accumulated multiple industry consultancy projects or editorial appointments, his promising work and contributions reflect the qualities of a rising researcher who is set to achieve even greater recognition at both national and international levels.

Impact and Influence

The potential impact of Mr. Patil’s research extends beyond academia, offering transformative possibilities in cancer treatment. By addressing the challenges of drug toxicity and inefficient targeting, his nanocarrier-based system has the potential to improve the quality of life for patients undergoing therapy. Moreover, his contributions set a strong foundation for future collaborations in nanomedicine, oncology research, and pharmaceutical technology. His influence also extends to his students, who benefit from his mentorship, guidance, and emphasis on research-driven learning. By bridging the gap between classroom knowledge and practical innovation, he inspires a new generation of pharmaceutical professionals to pursue impactful research that addresses pressing healthcare challenges.

Publications

Nonlocal thermoelastic diffusion analysis in a semi-infinite body subjected to thermal loading with memory effects.

Author: Jitendra Patil, Chandrakant Jadhav, Nitin Chandel & Vinod Varghese
Journal: Archive of Applied Mechanics
Year: 2025

Development and Characterization of AXT@Metal-Organic Framework: A Biocompatible, pH-Responsive Nanocarrier for Targeted Axitinib Delivery in MCF-7 Cancer Cells.

Author: Jayvadan K. Patel, Ujashkumar A. Shah, Pravin O. Patil, Jitendra H. Patil
Journal: Annales Pharmaceutiques Françaises
Year: 2025

Conclusion

Mr. Jitendra Hilal Patil exemplifies the qualities of a dedicated educator, an emerging researcher, and an innovator in pharmaceutical sciences. His academic journey, professional commitments, and research on pH-responsive nanocarriers reflect not only his scientific expertise but also his vision for improving global healthcare outcomes. With a growing body of impactful publications, a patent under process, and recognition as a promising voice in nanotechnology and drug delivery research, he continues to inspire both peers and students alike. Looking forward, his unwavering dedication positions him to make enduring contributions that bridge cutting-edge research with tangible benefits for society, leaving a meaningful legacy in academia and beyond.